Investment focus
HEMEX contributes as a smart money investor with strong clinical development expertise to the healthcare of tomorrow. With skin in the game, we act as a long-term partner that can assist in data collection.
Our investments are entirely focused on regulated healthcare products and technologies, which meet the United Nations’ sustainable development goals (SDGs 3.4, 3.7 and 3.d). Along with our follow-up investments in high performing portfolio companies, we aim to pursue 2-3 new projects per year, preferably from series A onwards.
“HEMEX empowers innovation in healthcare and actively supports portfolio companies to reach their next milestones to create shareholder value.”
Investment news
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of [...]
Read More
02
Feb
Feb
Moving forward fast – ASPIVIX is finishing the 2022 with a new investment and a generous grant.
We are thrilled to share that HEMEX is part of the investment consortium financing the [...]
Read More
17
Nov
Nov
hemotune raises CHF 7.25 million Series B1 funding
We are thrilled to share that HEMEX is part of the investment consortium financing the [...]
Read More
26
Apr
Apr